



## Review

# Soluble $\alpha$ Klotho concentration in the inferior vena cava of patients with primary aldosteronism



Hodaka Yamada<sup>a,\*</sup>, Makoto Kuro-o<sup>b</sup>, Shunsuke Funazaki<sup>a</sup>, Kohei Hamamoto<sup>c</sup>, Kazuo Hara<sup>a</sup>

<sup>a</sup> Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, Japan

<sup>b</sup> Division of Anti-aging Medicine, Center for Molecular Medicine, Jichi Medical University, 3311-1, Shimotsuke, Tochigi 329-0498, Japan

<sup>c</sup> Department of Radiology, School of Medicine, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, Japan

### ARTICLE INFO

#### Keywords:

Biomarker  
Renal function  
Soluble  $\alpha$ Klotho

### ABSTRACT

**Introduction:** Klotho, a key aging regulator, is predominantly expressed in the kidney. Various methods now enable the measurement of soluble  $\alpha$ Klotho blood levels in humans. Limited studies have explored the renal origin of circulating  $\alpha$ Klotho in humans.

**Methods:** Soluble  $\alpha$ Klotho in the inferior vena cava blood was measured using an enzyme-linked immunosorbent assay kit using blood samples from patients undergoing adrenal venous catheterization for close examination of primary aldosteronism.

**Results:** The concentration at the suprarenal inferior vena cava ( $476 \pm 68.2$ ) was significantly higher than that at the infrarenal inferior vena cava ( $434 \pm 74.8$ ) ( $p=0.018$ ), with a rate of change of 8.12 (2.3)%.

**Conclusions:** We demonstrate a step-up in  $\alpha$ Klotho concentration from the infrarenal to suprarenal vena cava in humans, supporting the kidney's origin of soluble  $\alpha$ Klotho in the bloodstream.

© 2024 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### Concentración de $\alpha$ -klotho soluble en la vena cava inferior de pacientes con aldosteronismo primario

### RESUMEN

**Introducción:** Klotho, un regulador clave del envejecimiento, se expresa predominantemente en el riñón. En la actualidad, diversos métodos permiten medir el nivel sanguíneo de  $\alpha$ -klotho soluble en humanos. Son escasos los estudios que han explorado el origen renal de la  $\alpha$ -klotho circulante en humanos.

#### Palabras clave:

Biomarcador  
Función renal  
 $\alpha$ -klotho soluble

\* Corresponding author.

E-mail address: [hyamada0510@jichi.ac.jp](mailto:hyamada0510@jichi.ac.jp) (H. Yamada).

<https://doi.org/10.1016/j.nefro.2024.04.001>

0211-6995/© 2024 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Métodos:** Se midió la  $\alpha$ -klotho soluble en la sangre de la vena cava inferior mediante un kit de ensayo inmunoabsorbente ligado a enzimas en muestras de sangre de pacientes con cateterismo venoso suprarrenal para un examen detallado del aldosteronismo primario.

**Resultados:** La concentración en la vena cava inferior suprarrenal ( $476 \pm 68,2$ ) fue significativamente superior a la de la vena cava inferior infrarrenal ( $434 \pm 74,8$ ) ( $p = 0,018$ ), con una tasa de variación del 8,12% (2,3%).

**Conclusiones:** Demostramos un aumento de la concentración de  $\alpha$ -klotho desde la vena cava infrarrenal a la suprarrenal en humanos, lo que respalda el origen renal de  $\alpha$ -klotho soluble en el torrente sanguíneo.

© 2024 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

The  $\alpha$ Klotho gene, initially discovered in mice, exhibits a deficiency-induced phenotype akin to human aging.<sup>1</sup> Highly expressed in the kidney, the Klotho protein functions as a receptor for fibroblast growth factor 23 (FGF23).<sup>2</sup> Klotho forms the FGFR-Klotho complex by binding to the FGF receptor (FGFR) via the receptor binding arm, serving as a physiological receptor for FGF23.<sup>2</sup> Known as a single-pass transmembrane protein, the Klotho protein undergoes cleavage by proteolytic enzymes, such as secretases, resulting in the secretion of its extracellular domain (ectodomain shedding).<sup>3</sup> In patients with chronic kidney disease, renal Klotho transcript significantly decreases, and soluble  $\alpha$ Klotho emerges as a promising early-stage kidney disease biomarker.<sup>4</sup> Current methods enable the measurement of soluble  $\alpha$ Klotho (sKlotho) levels. Although the origin of sKlotho was identified as  $\alpha$ Klotho highly expressed in the kidney,<sup>5</sup> measuring sKlotho in healthy humans through invasive tests like catheterization proves challenging. Consequently, few clinical studies have reported the renal origin of blood sKlotho in humans via catheter sampling. To address this, we opted to measure sKlotho in blood samples from patients undergoing adrenal venous sampling (AVS) for primary aldosteronism (PA) diagnosis. This approach aims to ascertain whether the kidneys secrete sKlotho and identify the clinical parameters associated with blood sKlotho.

## Patients and methods

### Patients

Eligible participants comprised patients with PA undergoing AVS for unilateral aldosterone-producing adenoma diagnosis at Jichi Medical University Saitama Medical Center during the 2019–2020 enrollment period. A total of 12 consecutive patients were enrolled, and PA was diagnosed following the clinical practice guidelines of the Japan Endocrine Society.<sup>6</sup> All AVS procedures were conducted by interventional radiologists, with 12 cases confirming successful AVS outcomes. This study, approved by the ethics committee of Jichi Medical University, Saitama Medical Center (no. S17-006), adhered to the ethical guidelines of the Declaration of Helsinki, and written informed consent was obtained from all subjects.

### Patient data collection


Basic clinical data, including age, sex, body mass index, and systolic or diastolic blood pressure before AVS, were collected. Additionally, serum sodium, potassium, estimated glomerular filtration rate (eGFR), hemoglobin (Hb), plasma renin activity (PRA), and plasma aldosterone concentrations (PAC) were measured. PAC and PRA were assessed using radioimmunoassay and enzyme immunoassay, respectively. Post-AVS, blood samples were promptly transported to the in-hospital laboratory, with the remaining samples frozen at  $-80^\circ$  after aldosterone concentration measurement. Soluble  $\alpha$ Klotho was measured using an enzyme-linked immunosorbent assay (ELISA) kit (soluble  $\alpha$ -Klotho Assay Kit, IBL, Japan). This ELISA kit, featuring intra-assay and inter-assay coefficients of variation (2.7–3.5% and 2.9–11.4%, respectively), showed no cross-reaction to  $\beta$ Klotho. Soluble  $\alpha$ Klotho was measured using triplicate blood samples collected from the infrarenal and suprarenal inferior vena cava (IVC).

### Statistical analysis

Continuous variables were presented as means ( $\pm$  standard error of the mean, SEM) or medians with interquartile range, while categorical variables were expressed as numbers or percentages. Linear correlations between soluble  $\alpha$ Klotho and clinical parameters were determined using Pearson's or Spearman's correlation coefficient analysis. The change in  $\alpha$ Klotho (%) at the suprarenal IVC level relative to the infrarenal IVC level (baseline, 0%) was calculated. Paired t-tests were employed to compare soluble  $\alpha$ Klotho (pg/mL) between the two groups. All analyses were conducted using EZR (Jichi Medical University Saitama Medical Center), a graphical user interface for R (The R Foundation for Statistical Computing, ver. 2.13.0), and a modified version of the R commander (ver. 1.6-3) with added statistical functions frequently used in biostatistics.<sup>7</sup> A significance level of  $p < 0.05$  was applied based on two-tailed calculation.

## Results

Table 1 presents the baseline characteristics of the 12 patients. In summary, the median age was 44.5 [43.8–56.0] years, with 50% ( $n=6$ ) being male. The mean eGFR was 78 ( $\pm 22$ )



**Fig. 1** – Blood soluble  $\alpha$ Klotho in the infrarenal and suprarenal vena cava (A). Change in  $\alpha$ Klotho (%) from the infrarenal to suprarenal vena cava (B). Relationship between serum sodium (mmol/L) levels and change in  $\alpha$ Klotho (%) (C). Relationship between PAC/PRA ratio (ARR) and change in Klotho (%) (D). Data are presented as mean with standard error of the mean (SEM). Black circles and bars indicate the mean and SEM of Klotho.

**Table 1** – Baseline characteristics of the 12 patients.

Clinical parameters	
Age (years)	44.5 [43.8–56]
Male, n (%)	6 (50)
Body mass index (kg/m <sup>2</sup> )	27.5 $\pm$ 7.1
Systolic blood pressure (mmHg)	136 $\pm$ 14
Diastolic blood pressure (mmHg)	83 $\pm$ 12
Serum potassium (mmol/L)	3.4 $\pm$ 0.56
Serum sodium (mmol/L)	142 $\pm$ 1.9
eGFR (mL/min/1.73 m <sup>2</sup> )	78 $\pm$ 22
Blood urea nitrogen (mg/dL)	13.5 $\pm$ 5.2
Creatinine (mg/dL)	0.80 $\pm$ 0.31
Hemoglobin (g/L)	13.7 $\pm$ 1.36
Plasma aldosterone concentrations (pg/mL)	261 $\pm$ 128
Plasma renin activity (ng/mL/h)	0.3 [0.2–0.4]
Aldosterone to renin ratio	751 [375–1266]

Data are presented as numbers (%) for categorical variables and as means ( $\pm$ standard error of the mean, SEM) or median with interquartile range (IQR) for continuous variables.

(mL/min/1.73 m<sup>2</sup>). For all 12 cases, the PAC/PRA ratio (ARR) exceeded 200 (pg/mL/ng/mL/h). All patients were on calcium channel blockers and three of them on concomitant alpha blockers. The patients were not taking any medications (mineralocorticoid receptor antagonists, beta blockers and diuretics) that could significantly affect ARR. The sKlotho concentration at the suprarenal IVC ( $476 \pm 74.8$ ) was significantly

**Table 2** – Relationship between change in  $\alpha$ Klotho (%) and clinical parameters.

Clinical parameters	r	p
Age (years)	-0.0141	0.965
Body mass index (kg/m <sup>2</sup> )	0.224	0.483
Systolic blood pressure (mmHg)	-0.171	0.596
Diastolic blood pressure (mmHg)	-0.186	0.563
Serum potassium (mmol/L)	0.663	0.0187
Serum sodium (mmol/L)	-0.773	0.003
eGFR (mL/min/1.73 m <sup>2</sup> )	0.021	0.948
Blood urea nitrogen (mg/dL)	-0.351	0.263
Creatinine (mg/dL)	-0.151	0.64
Hemoglobin (g/L)	0.004	0.989
Plasma aldosterone concentrations (pg/mL)	-0.235	0.463
Plasma renin activity (ng/mL/h)	0.819	0.001
Aldosterone to renin ratio	-0.79	0.004

eGFR, estimated glomerular filtration rate.

higher than that at the infrarenal IVC ( $434 \pm 68.2$ ) ( $p = 0.018$ ) (Fig. 1A), with a change rate of  $8.12 \pm 2.3\%$  (Fig. 1B). Correlations were observed between serum sodium level and the change in sKlotho ( $r = -0.773$ ,  $p = 0.003$ ) and between ARR and the change in sKlotho ( $r = -0.790$ ,  $p = 0.004$ ) (Fig. 1C and D). Table 2 shows the association between other clinical parameters and the rate of change in sKlotho. Renal function indices, such as BUN, Cr, and eGFR, did not exhibit significant associations with the rate of change in soluble  $\alpha$ Klotho.

## Discussion

In this study, we utilized ELISA to demonstrate in humans that the concentration of sKlotho at the suprarenal IVC surpasses that at the infrarenal IVC, affirming the kidney as the organ of origin for soluble  $\alpha$ Klotho. Hu et al. conducted a study with blood from catheterized patients ( $n=9$ ) evaluating heart failure and other conditions, revealing a step-up in sKlotho concentration from the infrarenal to suprarenal vena cava.<sup>8</sup> They measured sKlotho concentrations as protein levels using Western blot.<sup>8</sup> While catheterization is highly invasive and challenging in normal subjects, our study and theirs consistently depict a step-up in sKlotho concentration from the infrarenal to suprarenal vena cava, despite differing pathological conditions in the sampled patients.

Picciozzo et al. extensively examined renal Klotho release parameters in patients undergoing cardiac catheterization ( $n=22$ ), identifying oxygen uptake as a predictor of renal  $\alpha$ Klotho release.<sup>9</sup> Although our study did not assess oxygenation, we found a correlation between the change in sKlotho (%) and serum sodium and ARR. In PA, excessive aldosterone secretion induces sodium reabsorption, leading to increased fluid volume and hypertension.<sup>10</sup> Klotho(+/-) mice with elevated aldosterone levels develop hypertension,<sup>11</sup> suggesting a potential link between strong aldosterone production and impaired  $\alpha$ Klotho secretion. However, no relationship was observed between baseline blood pressure and the extent of sKlotho change. A recent large-scale study reported no difference in serum sKlotho levels measured by ELISA between individuals with and without hypertension.<sup>12</sup> On the other hand, partial correlation analysis, controlling for serum potassium levels, showed no correlation between changes in sKlotho and serum sodium ( $r=0.162$ ,  $p=0.677$ ) in this study. This could be a result of the pathophysiology of primary aldosteronism affecting serum potassium levels, but the small sample size precluded detailed statistical analysis. Further investigation is needed to explore the relationship between hyperaldosteronism severity and the extent of sKlotho change.

In our study, the change in sKlotho did not correlate with eGFR. Only two patients had an eGFR below 60 mL/min/1.73 m<sup>2</sup>, and none exhibited advanced renal impairment. Given aldosterone's renal damage effects<sup>13</sup> and the potential decrease in blood sKlotho levels from the early stages of renal damage,<sup>4,14,15</sup> it cannot be ruled out that subjects in this study might have lower blood sKlotho levels than healthy individuals. Blood sKlotho levels in our study were measured by ELISA rather than protein levels. Another study utilizing an immunoprecipitation immunoblot (IP-IB) assay showed a decrease in sKlotho in people with renal impairment.<sup>16</sup> Additionally, it has been reported that whether measured by ELISA or IP-IB, when a blood sample undergoes two or more freeze-thaw cycles, the value significantly decreases compared to zero or one thaw cycle.<sup>16</sup> Our study used samples frozen only once, and we believe that sample degradation did not have a significant effect. IB could measure distinct full-length proteins but is labor-intensive, while ELISA is a simple method, but the results are highly variable and less accurate than IB. In this study, the number of blood

samples obtained was small and klotho could not be measured in IB.

However, this study has several limitations. First, as a small-scale study, it was not feasible to thoroughly investigate the patient background under which the sKlotho step-up disappears. Other factors relevant to the FGF23-Klotho endocrine system, such as FGF23, serum calcium, phosphate, and parathyroid hormone, were also not evaluated. Analyzing whether these parameters affect serum sKlotho levels or the change in sKlotho should be considered. Second, sKlotho was not measured using any method other than ELISA to verify if a similar  $\alpha$ Klotho step-up exists.

## Conclusions

In conclusion, Klotho was measured using ELISA, demonstrating the step-up of  $\alpha$ Klotho concentration from infrarenal to suprarenal vena cava in humans. This supports the kidney's origin of circulating soluble  $\alpha$ Klotho.

## Conflicts of interest

None.

## Acknowledgments

The authors thank Enago for English editing.

## REFERENCES

1. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. *Nature*. 1997;390:45–51.
2. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. *J Biol Chem*. 2006;281:6120–3.
3. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, et al. Secreted klotho protein in sera and CSF: Implication for post-translational cleavage in release of klotho protein from cell membrane. *FEBS Lett*. 2004;565:143–7.
4. Hu MC, Kuro-o M, Moe OW. The emerging role of klotho in clinical nephrology. *Nephrol Dial Transplant*. 2012;27:2650–7.
5. Lindberg K, Amin R, Moe OW, Hu MC, Erben RG, Östman Wernerson A, et al. The kidney is the principal organ mediating klotho effects. *J Am Soc Nephrol*. 2014;25:2169–75.
6. Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. *Endocr J*. 2022;69:327–59.
7. Kanda Y. Investigation of the freely available easy-to-use software 'EZ' for medical statistics. *Bone Marrow Transplant*. 2013;48:452–8.
8. Hu MC, Shi M, Zhang J, Addo T, Cho HJ, Barker SL, et al. Renal production, uptake, and handling of circulating  $\alpha$ Klotho. *J Am Soc Nephrol*. 2016;27:79–90.
9. Picciozzo D, Murugavel A, Ansaldo F, Rosa GM, Sofia A, Milanese S, et al. The organ handling of soluble klotho in humans. *Kidney Blood Press Res*. 2019;44:715–26.
10. Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. *Lancet Diabetes Endocrinol*. 2021;9:876–92.

11. Zhou X, Chen K, Wang Y, Schuman M, Lei H, Sun Z. Antiaging gene klotho regulates adrenal CYP11B2 expression and aldosterone synthesis. *J Am Soc Nephrol.* 2016;27:1765–76.
12. Liang WY, Wang LH, Wei JH, Li QL, Li QY, Liang Q, et al. No significant association of serum klotho concentration with blood pressure and pulse wave velocity in a Chinese population. *Sci Rep.* 2021;11:2374.
13. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. *Hypertension.* 2004;43:841–8.
14. Neyra JA, Hu MC, Moe OW. Klotho in clinical nephrology: diagnostic and therapeutic implications. *Clin J Am Soc Nephrol.* 2020;16:162–76.
15. Kuro OM. Phosphate and klotho. *Kidney Int Suppl.* 2011;79:S20–3.
16. Barker SL, Pastor J, Carranza D, Quiñones H, Griffith C, Goetz R, et al. The demonstration of  $\alpha$ Klotho deficiency in human chronic kidney disease with a novel synthetic antibody. *Nephrol Dial Transplant.* 2015;30:223–33.